Developer docs
API playgroundTry for free, no card

Search company profiles

Ablaze Pharmaceuticals

Full company profile

uuid000264f

Namestring
Ablaze Pharmaceuticals
Legal namestring
Ablaze Pharmaceuticals
Company typeenum
Private
Founded yearint
2021
Short descriptiontext

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment, serving oncology healthcare providers across the Greater China market with a pipeline built on a $75M Series A.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
radiopharmaceutical therapy, targeted cancer therapy, oncology drug development, clinical-stage biopharmaceuticals, radiotherapy pipeline
Industry1 code
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Radiopharmaceutical Oncology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue Stage
TypeSubscription Recurring
Description

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company currently in the pre-revenue phase. The company is developing targeted radiopharmaceutical therapies for cancer and has not yet commercialized any products. Revenue generation is anticipated upon successful development and regulatory approval of TRT products in the Greater China market.

prnasia.com
Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment. The company is building a pipeline of TRT products intended to precisely target cancer cells while minimizing damage to healthy tissue, with a commercial focus on the Greater China market. Ablaze has not yet commercialized any products and remains pre-revenue.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Targeted Radiopharmaceutical Therapy (TRT) Pipeline
CategoryRadiopharmaceutical Oncology
Description

Clinical-stage pipeline of targeted radiopharmaceutical therapies designed to precisely target cancer cells while minimizing damage to healthy tissue, intended for oncology healthcare providers and institutions in the Greater China market upon regulatory approval.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeBroad incumbent
Description

Global pharma with Pluvicto and Lutathera, the leading commercial radioligand therapies for oncology. Most comparable as the dominant commercial benchmark Ablaze's TRT assets would compete against or partner with.

TypeDirect peer
Description

Radiopharmaceutical-focused company with both diagnostic and therapeutic assets (e.g., PNT2002 prostate cancer program). Direct peer in TRT development and commercialization in oncology.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing Lu-177 and Ac-225-based TRT assets for oncology, acquired by Eli Lilly for ~$1.4B in 2023. Direct peer validating strategic-acquisition demand for radiopharma platforms.

TypeDirect peer
Description

Clinical-to-commercial radiopharmaceutical company developing targeted diagnostic and therapeutic agents for oncology. Direct comparable in modality (TRT), pipeline stage, and commercial pathway.

TypeRegional player
Description

China-headquartered biopharmaceutical company with a large oncology pipeline and established commercial infrastructure in Greater China. Comparable as a regional oncology peer that demonstrates the scale and partnership dynamics Ablaze would face domestically.

TypeBroad incumbent
Description

Developed and markets Xofigo (radium-223), the first commercially significant radiopharmaceutical in oncology. Comparable as a broad incumbent with established radiopharma infrastructure and global commercial reach.

TypeDirect peer
Description

Global radiopharmaceutical company with established PET and SPECT diagnostics and emerging therapeutic capabilities. Comparable as a vertically integrated radiopharma peer.

TypeDirect peer
Description

Radiopharmaceutical company developing both diagnostic and therapeutic targeted radionuclide therapies, with proprietary isotope production capacity. Comparable in modality and integrated supply chain strategy.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing actinium-225 TRT for solid tumors, acquired by Bristol-Myers Squibb for ~$4.1B in 2024. Highly comparable modality focus and stage; the exit value defines the addressable valuation ceiling for early TRT peers like Ablaze.

10China Medical System Holdings
TypeRegional player
Description

China-focused specialty pharma with oncology and cardiovascular franchises, including licensing activities for innovative modalities. Comparable regional player that could be a partner or competitor for novel oncology therapies in Greater China.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ablaze Pharmaceuticals

Radiopharmaceutical Oncologyablazepharma.com

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment, serving oncology healthcare providers across the Greater China market with a pipeline built on a $75M Series A.

Ablaze Pharmaceuticals firmographics

Firmographics
Name
Ablaze Pharmaceuticals
Legal name
Ablaze Pharmaceuticals
Website
https://ablazepharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment, serving oncology healthcare providers across the Greater China market with a pipeline built on a $75M Series A.
Ownership category
akta.pro rank

Ablaze Pharmaceuticals industry classification

Industry
Product category
Radiopharmaceutical Oncology
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Radiopharmaceutical therapy
  • Targeted cancer therapy
  • Oncology drug development
  • Clinical-stage biopharmaceuticals
  • Radiotherapy pipeline

Where Ablaze Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Markets served

Ablaze Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pre-revenue Stage: Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company currently in the pre-revenue phase. The company is developing targeted radiopharmaceutical therapies for cancer and has not yet commercialized any products. Revenue generation is anticipated upon successful development and regulatory approval of TRT products in the Greater China market.

Go-to-market motion1 record

Ablaze Pharmaceuticals product offering

Product offering

Core offering

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment. The company is building a pipeline of TRT products intended to precisely target cancer cells while minimizing damage to healthy tissue, with a commercial focus on the Greater China market. Ablaze has not yet commercialized any products and remains pre-revenue.

Differentiator

Problem solved

Functional benefit

Products and services

  • Targeted Radiopharmaceutical Therapy (TRT) Pipeline Clinical-stage pipeline of targeted radiopharmaceutical therapies designed to precisely target cancer cells while minimizing damage to healthy tissue, intended for oncology healthcare providers and institutions in the Greater China market upon regulatory approval.

Companies that use Ablaze Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Ablaze Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ablaze Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators2 records

Ablaze Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Global pharma with Pluvicto and Lutathera, the leading commercial radioligand therapies for oncology. Most comparable as the dominant commercial benchmark Ablaze's TRT assets would compete against or partner with.
  • Bayer: Developed and markets Xofigo (radium-223), the first commercially significant radiopharmaceutical in oncology. Comparable as a broad incumbent with established radiopharma infrastructure and global commercial reach.

Direct peers

  • Lantheus Holdings: Radiopharmaceutical-focused company with both diagnostic and therapeutic assets (e.g., PNT2002 prostate cancer program). Direct peer in TRT development and commercialization in oncology.
  • Point Biopharma: Clinical-stage radiopharmaceutical company developing Lu-177 and Ac-225-based TRT assets for oncology, acquired by Eli Lilly for ~$1.4B in 2023. Direct peer validating strategic-acquisition demand for radiopharma platforms.
  • Telix Pharmaceuticals: Clinical-to-commercial radiopharmaceutical company developing targeted diagnostic and therapeutic agents for oncology. Direct comparable in modality (TRT), pipeline stage, and commercial pathway.
  • Curium: Global radiopharmaceutical company with established PET and SPECT diagnostics and emerging therapeutic capabilities. Comparable as a vertically integrated radiopharma peer.
  • ITM Isotope Technologies Munich: Radiopharmaceutical company developing both diagnostic and therapeutic targeted radionuclide therapies, with proprietary isotope production capacity. Comparable in modality and integrated supply chain strategy.
  • RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225 TRT for solid tumors, acquired by Bristol-Myers Squibb for ~$4.1B in 2024. Highly comparable modality focus and stage; the exit value defines the addressable valuation ceiling for early TRT peers like Ablaze.

Regional players

  • Innovent Biologics: China-headquartered biopharmaceutical company with a large oncology pipeline and established commercial infrastructure in Greater China. Comparable as a regional oncology peer that demonstrates the scale and partnership dynamics Ablaze would face domestically.
  • China Medical System Holdings: China-focused specialty pharma with oncology and cardiovascular franchises, including licensing activities for innovative modalities. Comparable regional player that could be a partner or competitor for novel oncology therapies in Greater China.

Market position

Customer concentration

Ablaze Pharmaceuticals social profiles

Digital presence

Ablaze Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ablaze Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Ablaze Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ablaze Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ablaze Pharmaceuticals

What does Ablaze Pharmaceuticals do?

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted radiopharmaceutical therapies (TRT) for cancer treatment. The company is building a pipeline of TRT products intended to precisely target cancer cells while minimizing damage to healthy tissue, with a commercial focus on the Greater China market. Ablaze has not yet commercialized any products and remains pre-revenue.

Is Ablaze Pharmaceuticals a public or private company?

Ablaze Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ablaze Pharmaceuticals founded?

Ablaze Pharmaceuticals was founded in 2021. It employs 1 to 10 people.

Where is Ablaze Pharmaceuticals based?

Ablaze Pharmaceuticals is headquartered in Shanghai, China, in the Asia region.

How does Ablaze Pharmaceuticals make money?

One revenue line is on record: pre-revenue Stage.

Who are Ablaze Pharmaceuticals's main competitors?

Broad incumbents on record are Novartis and Bayer. Direct peers are Lantheus Holdings, Point Biopharma, Telix Pharmaceuticals, Curium, ITM Isotope Technologies Munich and RayzeBio. Regional players are Innovent Biologics and China Medical System Holdings.

Does Ablaze Pharmaceuticals have an API?

No public API is recorded for Ablaze Pharmaceuticals.

What industry is Ablaze Pharmaceuticals in?

Ablaze Pharmaceuticals's product category is Radiopharmaceutical Oncology. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAblaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater ChinaAblaze Pharmaceuticals announced development plans for a first-in-class GPC3-targeted radiopharmaceutical therapy for liver cancer in the Greater China region, licensed from RayzeBio. This strategic collaboration leverages RayzeBio's discovery strengths and Ablaze's clinical development expertise to address significant unmet medical needs in the Chinese market.PR NewswireAblaze Pharmaceuticals plant die Entwicklung einer innovativen GPC3 Targeted Radiopharmaceutical Therapy zur Behandlung von Leberkrebs im Großraum ChinaAblaze Pharmaceuticals announced plans to develop a GPC3-targeted radiopharmaceutical therapy for liver cancer treatment in Greater China, licensing the proprietary GPC3 targeting peptide from RayzeBio under an existing agreement.PR NewswireAblaze Pharmaceuticals desarrollará una terapia radiofarmacéutica dirigida a GPC3 para el cáncer de hígadoAblaze Pharmaceuticals announced plans to develop a novel radiopharmaceutical therapy targeting GPC3 for liver cancer in mainland China, leveraging a licensed targeting peptide from RayzeBio under an existing agreement. Ablaze will be responsible for clinical development and commercialization in the region, while the collaboration combines RayzeBio's TRT discovery expertise with Ablaze's radiopharmaceutical infrastructure in China. GPC3 is a clinically relevant biomarker expressed specifically in liver cancer but absent in normal liver tissue, and approximately half of the world's new liver cancer cases and deaths occur in China, representing over 410,000 new cases and 390,000 deaths annually.PR NewswireAblaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater ChinaAblaze Pharmaceuticals announced plans to develop a first-in-class GPC3 targeted radiopharmaceutical therapy for liver cancer in Greater China, licensed from RayzeBio under an existing agreement. Ablaze will be responsible for clinical development and commercialization of the product in the region. The announcement highlights a significant unmet medical need, with liver cancer accounting for over 410,000 new cases and 390,000 deaths in China in 2020.PR NewswireAblaze Pharmaceuticals compte développer une radiothérapie ciblée innovante ciblant le GPC3 et destinée à traiter le cancer du foie en Grande ChineAblaze Pharmaceuticals a annoncé son intention de développer un candidat médicament peptidique de radiothérapie ciblée ciblant le GPC3 pour le traitement du cancer du foie, acquis sous licence auprès de RayzeBio, en vue de sa commercialisation en Grande Chine. Ce candidat peptidique a démontré des résultats prometteurs en modèles précliniques, notamment une liaison puissante et sélective au GPC3, une internalisation cellulaire rapide et une absorption tumorale soutenue. Le cancer du foie représente un besoin médical majeur non satisfait en Chine, qui concentre près de la moitié des nouveaux cas et décès dans le monde.PR NewswireAblaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical TherapiesAblaze Pharmaceuticals announced a development and manufacturing services agreement with Yonghe Pharmaceutical Technology to develop targeted radiopharmaceutical therapy products for cancer treatment. Under the agreement, Yonghe will serve as the CDMO partner providing production process development and cGMP manufacturing services from preclinical through clinical stages. This partnership is intended to advance Ablaze's TRT pipeline for the benefit of cancer patients in China, with TRT described as a proven approach for treating multiple cancers.PR NewswireAblaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical TherapiesIn July 2022, Ablaze Pharma signed a strategic agreement with the Wenjiang District Government of Chengdu to build an R&D and manufacturing center for targeted radiopharmaceutical therapies in Chengdu Medical City. The facility will occupy approximately 26,000㎡ of industrial land with an initial investment of 100 million USD, focusing on five anti-tumor varieties including Ac-225 and Lu-177. Ablaze Pharma aims to leverage Sichuan Province's nuclear science and technology resources to establish an ecosystem covering the full radiopharmaceutical value chain from discovery to commercialization.FinSMEsAblaze Pharmaceuticals Raises $75M in Series A FinancingAblaze Pharmaceuticals raised $75M in Series A financing co-led by Vivo Capital and AdvanTech Capital. The funds will support its pipeline of targeted radiopharmaceutical therapies for solid tumors, expand leadership, and build infrastructure. The company also holds an exclusive China development and commercial right to RayzeBio products.PR NewswireAblaze Pharmaceuticals lanza una financiación Serie A de 75 millones de dólaresAblaze Pharmaceuticals announced the closing of a $75 million Series A funding round co-led by Vivo Capital and AdvanTech Capital, with participation from multiple investment firms including RayzeBio, Nan Fung Life Sciences, venBio Partners, and others. The company plans to use the proceeds to build a pipeline of targeted radiopharmaceutical therapies for treating solid tumors and expand its leadership team and manufacturing infrastructure in China. Ablaze was founded in 2021 in partnership with San Diego-based RayzeBio, Inc., to develop and commercialize TRT products for the Chinese market.PR NewswireAblaze Pharmaceuticals lance un financement de série A de 75 millions de dollars pour apporter de nouveaux produits radiopharmaceutiques ciblés afin de traiter les patients atteints de cancer sur le mAblaze Pharmaceuticals announced a $75 million Series A funding round to develop targeted radiopharmaceutical treatments for cancer patients in China. The investment was co-led by Vivo Capital and AdvanTech Capital, with participation from several other venture capital firms including Samsara BioCapital and Venrock Healthcare Capital Partners.